
Thursday, September 15, 2022 7:27:47 AM
Sooner or later it will go much higher! Consolidation will be over soon. Nice chance to buy some more...

Liked By
Spread the love. Be the first to like this post!
Recent IMTX News
- Annual and Transition Report (foreign Private Issuer) (20-f) • Edgar (US Regulatory) • 03/22/2023 10:57:22 AM
- Immatics Announces Full Year 2022 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/21/2023 11:31:38 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 03/13/2023 10:31:17 AM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/14/2023 10:24:03 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/14/2023 09:02:47 PM
- Schedule 13g<br /> (sc 13g) • Edgar (US Regulatory) • 02/07/2023 11:07:40 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 01/09/2023 12:07:26 PM
- SVB Securities Sticks to Their Buy Rating for Immatics (IMTX) • TipRanks • 11/21/2022 04:15:41 AM
- Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX) • TipRanks • 11/17/2022 11:15:19 PM
- Immatics Announces Third Quarter 2022 Financial Results and Business Update • GlobeNewswire Inc. • 11/17/2022 12:00:00 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 11/10/2022 02:12:01 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 10/18/2022 12:07:11 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 10/11/2022 10:31:44 AM
- Immatics Rises on $110M Underwritten Offering • TipRanks • 10/10/2022 01:28:02 PM
- Immatics Announces $110 Million Underwritten Offering of Ordinary Shares • GlobeNewswire Inc. • 10/10/2022 11:37:42 AM
- Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME • GlobeNewswire Inc. • 10/10/2022 11:36:02 AM
- SVB Securities Remains a Buy on Immatics (IMTX) • TipRanks • 09/14/2022 03:45:55 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 09/12/2022 11:01:18 AM
- Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Biogen (BIIB) and Bicycle Therapeutics (BCYC) • TipRanks • 09/11/2022 06:20:19 AM
- Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 • GlobeNewswire Inc. • 09/10/2022 07:06:16 AM
- SVB Securities Sticks to Its Buy Rating for Immatics (IMTX) • TipRanks • 09/07/2022 04:05:18 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 08/23/2022 11:13:27 AM
- Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME • GlobeNewswire Inc. • 08/23/2022 11:00:00 AM
- SVB Securities Keeps Their Buy Rating on Immatics (IMTX) • TipRanks • 08/11/2022 03:16:13 AM
- Chardan Capital Remains a Buy on Immatics (IMTX) • TipRanks • 08/09/2022 10:35:12 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM